Benchmarking Mendelian Randomization methods for causal inference using genome-wide association study summary statistics

Xianghong Hu^{1,2}, Mingxuan Cai⁴, Jiashun Xiao⁵, Xiaomeng Wan^{1,2}, Zhiwei Wang^{1,2}, Hongyu Zhao ^{*6}, and Can Yang ^{*1,2,3}

¹Department of Mathematics, The Hong Kong University of Science and Technology, Hong Kong, China.

²Guangzhou HKUST Fok Ying Tung Research Institute, Guangzhou 511458, China.

³Big Data Bio-Intelligence Lab, The Hong Kong University of Science and Technology, Hong Kong SAR, China

⁴Department of Biostatistics, City University of Hong Kong, Hong Kong, China.

⁵Shenzhen Research Institute of Big Data, Shenzhen 518172, China.

 $^6\mathrm{Department}$ of Biostatistics, Yale School of Public Health, New Haven, CT 06520, USA.

Abstract

Mendelian Randomization (MR), which utilizes genetic variants as instrumental variables (IVs), 1 has gained popularity as a method for causal inference between phenotypes using genetic data. 2 While efforts have been made to relax IV assumptions and develop new methods for causal 3 inference in the presence of invalid IVs due to confounding, the reliability of MR methods 4 in real-world applications remains uncertain. To bridge this gap, we conducted a benchmark 5 study evaluating 15 MR methods using real-world genetic datasets. Our study focused on 6 three crucial aspects: type I error control in the presence of various confounding scenarios 7 (e.g., population stratification, pleiotropy, and assortative mating), the accuracy of causal 8 effect estimates, replicability and power. By comprehensively evaluating the performance of 9 compared methods over one thousand pairs of exposure-outcome traits, our study not only 10

^{*}To whom correspondence may be addressed: Hongyu Zhao (hongyu.zhao@yale.edu) and Can Yang (macyang@ust.hk).

provides valuable insights into the performance and limitations of the compared methods but
 also offers practical guidance for researchers to choose appropriate MR methods for causal
 inference.

14 Introduction

Understanding the causal relationships between exposures and outcomes is crucial in biomedical 15 and social science research, as it enables discoveries in etiology, aids in drug development, and 16 informs policy-making. While randomized controlled trials (RCTs) are considered the gold 17 standard for assessing causality, they can be time-consuming, costly, and sometimes ethically 18 challenging [1]. Causal inference based on observational data presents its own challenges. 19 such as unmeasured confounding or reverse causality. Mendelian randomization (MR) offers a 20 promising approach to performing causal inference using observed genetic data [2, 3]. According 21 to Mendel's law of inheritance, genotypes are randomly inherited from parents to offspring, 22 thereby ideally being independent of environmental confounding factors. This characteristic 23 motivates researchers to explore genetic data in order to study the causal effects of one phenotype 24 (exposure) on another phenotype (outcome). In recent years, MR has gained popularity due 25 to the availability of summary statistics from thousands of genome-wide association studies 26 (GWAS) covering a wide range of phenotypes. Leveraging the rich genetic data resources 27 available, researchers worldwide can investigate the potential causal relationships between 28 exposures and outcomes of interest, encompassing diverse applications such as identifying disease 29 risk causation [4], providing evidence for epidemiological associations [5], and prioritizing targets 30 in drug development [6, 7]. 31

To perform causal inference using MR approaches, genetic variants (typically Single 32 Nucleotide Polymorphisms, i.e., SNPs) serve as instrument variables (IVs). A valid IV should 33 satisfy the following three IV assumptions [8, 9]: (1) it is associated with the exposure of 34 interest; (2) it is not associated with the confounders of the exposure and outcome traits; and 35 (3) it affects the outcome only through the exposure of interest. However, these assumptions 36 underlying MR are often too strong to be satisfied in real applications. In recent years, much 37 effort has been devoted to relaxing these assumptions and new MR methods have been designed 38 to enable causal inference in the presence of invalid IVs. To name a few, MR-PRESSO [10], 39 cML-MA [11], and MR-Lasso [12] use outlier detection to identify invalid IVs and remove them 40 from the MR analysis. MR-Robust[12], weighted-median [13], and weighted-mode [14] use 41 outlier-robust techniques to mitigate the effects of invalid IVs. Additionally, methods like Egger 42 [15], RAPS [16], and BWMR [17] employ probabilistic models to correct for different types of 43 pleiotropy, while CAUSE [18], MRAPSS [19], MRMix [20], MR-ConMix [21], and MR-CUE 44 [22] employ mixture component models to characterize valid and invalid signals, enabling causal 45 inference based on the component of valid signals. 46

Although considerable progress has been made in the development of MR methods, their robustness to the violation of underlying assumptions in real-world applications remains largely unclear. Due to the complexity of human genetics, several factors can significantly impact the performance of existing MR methods. Firstly, complex traits often exhibit high polygenicity, meaning that individual SNPs have small effect sizes. To satisfy the IV assumption (1), researchers select SNPs as IVs from the exposure GWAS using a *p*-value threshold (IV

threshold). However, this selection process may inadvertently include weakly associated SNPs, 53 which can introduce bias into MR estimates. Moreover, using the same exposure dataset for 54 IV selection and MR estimation in two-sample MR settings can induce non-ignorable bias, 55 known as selection bias [16]. Second, population stratification and family-level confounders 56 (e.g., assortative mating and dynastic effects) are well-known issues in population-based GWAS, 57 which can introduce associations between genetic instruments and unobserved confounders 58 [23, 24, 25], leading to the violation of IV assumption (2). Despite the significance of population 59 stratification and family-level confounders, many existing MR methods have not explicitly 60 accounted for these. Third, pleiotropy is a ubiquitous phenomenon in human genetics, referring 61 to a single genetic variant influencing multiple traits, thereby violating IV assumption (3) [26]. 62 Carefully accounting for pleiotropy is crucial for reliable causal inference using MR approaches. 63 Given these complexities, it is crucial to conduct benchmarking studies to assess the reliability 64 of existing MR methods when their model assumptions may be violated. Such studies would 65 provide valuable insights into the performance and limitations of these methods in real-world 66 scenarios. 67

In this study, we present a benchmarking analysis of MR methods for causal inference 68 with real-world genetic datasets. Our focus is on MR methods that utilize GWAS summary 69 statistics as input, as they do not require access to individual-level GWAS data and are widely 70 applicable. Specifically, we consider 15 MR methods, including the standard IVW (fixed) [27] 71 and IVW (random) [28] and 13 other advanced MR methods: Egger, RAPS, Weighted-median, 72 Weighted-mode, MR-PRESSO, MRMix, cML-MA, MR-Robust, MR-Lasso, MR-CUE, CAUSE, 73 MRAPSS and MR-ConMix. To assess the performance of these MR methods, we utilized 74 real-world datasets and focused on three key aspects: type I error control, the accuracy of 75 causal effect estimates, and replicability. Particularly, in evaluating type I error control, we 76 used GWAS summary-level datasets for over one thousand exposure-outcome trait pairs of no 77 causal effect, serving as negative controls. These trait pairs were carefully selected to represent 78 scenarios involving confounding factors, such as population stratification and pleiotropy. We 79 conducted a comparison between population-based MR and family-based MR to evaluate the 80 influence of family-level confounders. Through our comprehensive experiments using real-world 81 datasets, we found that the performance of MR methods is heavily influenced by confounding 82 factors that arise from various sources in practical scenarios. We also investigated the influence 83 of summary-level data pre-processing steps, such as the inclusion of SNPs with different minor 84 allele frequencies and the choice of reference genome panels. Our study offers practical guidelines 85 for researchers in choosing appropriate MR methods and improving the reliability of causal 86 inference in MR analyses. 87

${ m \ \ sec} { m \ Results}$

⁸⁹ The experimental design for benchmarking MR methods

We conducted a benchmarking of 15 summary-level data-based MR methods, which were categorized into four groups: IVW-class, outlier detection and removal methods, model-based methods, and outlier robust methods (Fig. 1-A, Table S1, section 1 of the supplementary note). The procedure for running the MR methods is outlined in Fig. 1-B and described in detail in

the Method section. To ensure a comprehensive evaluation, we utilized real-world datasets and focused on three crucial aspects: type I error control, the accuracy of causal effect estimates, replicability and power (see Fig. 1-C).

To assess type I error control, we applied the MR methods to GWAS summary statistics 97 for three sets of exposure-outcome trait pairs with no causal effect. The three sets of trait 98 pairs represented three different confounding scenarios, including (a) population stratification. 99 (b) pleiotropy, and (c) family-level confounders. Specifically, in scenario (a), we used 1,130 100 trait pairs between 226 exposures from UK Biobank and five negative control outcomes to 101 investigate the influence of population stratification on MR methods (Supplementary data 1). 102 The negative control study was designed carefully based on two criteria: First, the outcomes 103 should not be causally affected by the exposures. Second, both the outcomes and exposures 104 should be affected by population stratification. In this scenario, we chose four hair color-related 105 traits and tanning ability as negative control outcomes. These traits are mainly determined at 106 birth and are likely influenced by population stratification [24]. In scenario (b), we analyzed 107 trait pairs between 11 exposures and seven negative control outcomes. The selected exposures 108 included five adult behavior-related traits and six aging-related traits, while the negative 109 control outcomes were seven childhood-related traits (Supplementary data 2). This choice 110 was based on the convention that traits developed after adulthood are unlikely to affect traits 111 developed before adulthood causally. These negative control outcomes exhibited non-zero 112 genetic correlations with most of the exposures (SFig S4), indicating that pleiotropy is a major 113 confounder here. In scenario (c), we analyzed 82 trait pairs using both population-based GWASs 114 and family-based GWASs to examine the influence of family-level confounders (Supplementary 115 data 3). Population-based GWAS estimates, which are derived from unrelated individuals, are 116 known to be susceptible to bias due to the influence of family-level confounders. Conversely, 117 family-based GWAS designs offer the advantage of accounting for the effects of family-level 118 confounders when estimating GWAS effects [29, 30]. By comparing the results of MR analyses 119 obtained from the population-based GWAS and family-based GWAS designs, we can assess 120 the effectiveness of MR methods in controlling for type I errors in the presence of family-level 121 confounding, such as assortative mating and dynastic effects. For this scenario, we required 122 the trait pairs to be genetically uncorrelated. Based on the principle "no correlation implies 123 no causal relationship", we treated these trait pairs as negative controls. By applying MR 124 methods to the three datasets representing different confounding scenarios, we investigated 125 their ability to control type I errors in the presence of different confounding factors. 126

In evaluating the accuracy of causal effect estimates, we examined six pairs of traits where 127 each pair comprised the same trait as both the "exposure" and the "outcome" (Supplementary 128 data 4). The UK Biobank dataset was divided equally to obtain exposure and outcome GWAS 129 data. Importantly, the true causal effects in this analysis were known to be exactly one 130 [16, 31]. This design allowed us to assess the accuracy of MR methods in estimating causal 131 effects. To evaluate replicability and power, we focused on a positive control example involving 132 low-density lipoprotein cholesterol (LDL-C) and coronary artery disease (CAD). We applied 133 all the MR methods to six GWAS datasets for LDL-C obtained from five distinct studies 134 (Supplementary data 5). By analyzing multiple GWAS datasets for the same trait, we assessed 135 the replicability of the causal effect estimates across different study designs and sample sizes. 136 Detailed information about the datasets used in this study can be found in the Method section, 137

¹³⁸ and specific details regarding the sources of GWAS data are summarized in Stable 1-5.



Figure 1: Experimental design for benchmarking MR methods. A We compared the performance of 15 GWAS summary-level data-based MR Methods. B We designed a four-step procedure for running MR methods. C We used real-world datasets to evaluate the performance of MR methods on three aspects: Type I error control in three confounding scenarios, including (a) population stratification, (b) pleiotropy, and (c) family-level confounders, the accuracy of causal effect estimates, replicability and power.

Throughout the evaluation process, our first step was to assess the performance of MR methods when IVs were selected based on the default *p*-value thresholds in the exposure GWAS. Specifically, among the compared methods, MR-APSS and MR-CUE utilized a default IV threshold of 5×10^{-5} , CAUSE employed a default IV threshold of 1×10^{-3} , and the remaining methods required strong IVs with a default IV threshold of 5×10^{-8} . All of the compared MR

methods, except for MR-CUE, require Plink LD clump ($r^2 = 0.001, 1$ Mb) to obtain independent 144 SNPs as IVs. Furthermore, we introduced variations in the *p*-value thresholds used for IV 145 selection to examine the methods' performance across a range of IV thresholds, including a 146 stringent threshold of 5×10^{-8} , as well as more relaxed thresholds of 5×10^{-7} , 5×10^{-6} , and 147 5×10^{-5} . As the IV thresholds become looser, the number of IVs, including both valid IVs and 148 invalid IVs, may increase. Moreover, the number of IVs with weaker effects may also increase. 149 This analysis allowed us to assess the robustness of these methods in handling invalid IVs due 150 to confounding factors and determine whether they are sensitive to the choice of IVs used in 151 MR analysis. 152

¹⁵³ MR-APSS, Egger, Weighted-mode, and CAUSE achieve better performance ¹⁵⁴ in type I error control

We conducted a comprehensive evaluation to assess the effectiveness of 15 MR methods in 155 controlling type I errors across various confounding scenarios. The evaluation utilized three 156 real-world datasets and focused on three specific scenarios: population stratification, pleiotropy, 157 and family-level confounders. To evaluate the performance of these methods, we generated QQ 158 plots to visualize the *p*-values produced by each method for the three datasets, as shown in Figs. 159 2-4. These QQ plots provide a visual tool to identify deviations from the expected diagonal 160 line, which helps determine if the methods are generating systematically inflated or deflated 161 *p*-values. In this analysis, we initially assessed the MR methods using their default setting for 162 IV selection. Specifically, we first examined the performance of MR-APSS and MR-CUE at 163 the IV threshold of 5×10^{-5} , the performance of CAUSE at the IV threshold of 1×10^{-3} , and 164 the performance of other methods at the IV threshold of 5×10^{-8} . 165

In scenario (a), characterized by the presence of strong population stratification, MR-APSS 166 and Weighted-mode consistently generated well-calibrated p-values, using their default IV 167 thresholds. However, Egger's *p*-values were slightly inflated. The *p*-values of CAUSE initially 168 showed deflation but later exhibited inflation. Further analysis of causal effect estimates 169 reveals that CAUSE's confidence intervals are more reliable compared to its *p*-values. On 170 the other hand, the remaining 11 methods, including IVW (fixed), IVW (random), RAPS. 171 Weighted-median, MR-PRESSO, MRMix, cML-MA, MR-Robust, MR-Lasso, MR-CUE, and 172 MR-ConMix, exhibited highly inflated *p*-values at the default IV threshold of 5×10^{-8} . Notably, 173 IVW (fixed) demonstrated the most severe inflation, which is expected as it is a basic MR 174 method that does not account for IV invalidity, leading to bias and inflation in the estimates. 175 While other methods incorporated different assumptions to address invalid IVs, they still failed 176 to effectively control type I error inflation. These findings highlight the limitations of existing 177 methods in handling scenarios involving strong population stratification, where their model 178 assumptions do not align well with real-world situations. 179

In scenario (b), where pleiotropy is present, several methods exhibited effective control of type I errors. Notably, CAUSE, Egger, MR-APSS, and Weighted-mode demonstrated the absence of inflated *p*-values, indicating their capability to address pleiotropy. However, it was observed that CAUSE's *p*-values were deflated. On the other hand, several other methods, including IVW (random), MR-Lasso, MR-PRESSO, RAPS, Weighted-median, IVW (fixed), cML-MA, MR-ConMix, and MR-Robust, exhibited inflated *p*-values at the default IV threshold.

Notably, IVW (fixed), cML-MA, and MR-ConMix showed more pronounced inflation compared to the other methods. Despite these methods' primary focus on addressing pleiotropy, their performance in controlling type I errors was not entirely satisfactory. This observation indicates the ongoing challenge in effectively handling pleiotropy in MR analysis and the need for further methodological advancements.

In scenario (c), we conducted a comparison between the results of MR methods using 191 both population-based and family-based GWAS data for 82 negative control trait pairs. The 192 objective was to assess the effectiveness of MR methods in controlling for type I errors in 193 the presence of family-level confounders. The QQ plots for MR methods at their default IV 194 thresholds, using both population-based GWAS and within-family-based GWAS summary-level 195 data, are depicted in Fig. 4. When using population-based GWAS data, Egger, Weighted-mode, 196 and MRMix did not yield inflated *p*-values. CAUSE produced deflated *p*-values, and MR-APSS 197 exhibited very slight inflation in the *p*-values. On the other hand, other methods such as IVW 198 (fixed), MR-Lasso, cML-MA, and MR-CUE produced inflated *p*-values, indicating challenges in 199 adequately addressing family-level confounding using these methods. However, when utilizing 200 family-based GWAS data, all MR methods produced well-calibrated p-values, demonstrating 201 effective control of type I error inflation. Our results provide further evidence for the usefulness 202 of family-based MR in mitigating the influence of family-level confounders in MR analysis. 203

²⁰⁴ IV selection largely affects the performance of MR methods

We conducted a comprehensive investigation into the performance of various MR methods by 205 analyzing their behavior across a range of IV thresholds, including a stringent threshold of 206 5×10^{-8} , as well as more relaxed thresholds of 5×10^{-7} , 5×10^{-6} , and 5×10^{-5} . The QQ plots 207 in Figs. 2 and 3 depict the results obtained in confounding scenarios (a) and (b), respectively. 208 From these plots, we can observe that MR-APSS, Egger, and weighted-mode consistently 209 generated well-calibrated *p*-values across varying IV thresholds. However, it is worth noting 210 that the *p*-values obtained from CAUSE were consistently deflated. On the other hand, the 211 remaining 11 methods, including IVW (fixed), IVW (random), RAPS, Weighted-median, MR-212 PRESSO, MRMix, cML-MA, MR-Robust, MR-Lasso, MR-CUE, and MR-ConMix, exhibited 213 substantially inflated *p*-values. Furthermore, the degree of *p*-value inflation tended to increase 214 as the IV threshold became looser. MRMix was an exception with slightly inflated p-values 215 at a less stringent IV threshold of 5×10^{-5} but more inflated *p*-values at the IV threshold of 216 5×10^{-8} , as observed in Fig. 3. This observation suggests that MRMix can be sensitive to the 217 number of IVs used. It tends to produce more false positives when there is a limited number of 218 IVs. Our results indicate that causal inference results obtained from most of the methods are 219 sensitive to the IV threshold. 220



Figure 2: Evaluation of type I error control in confounding scenario (a) of population stratification. Type I error is evaluated by quantile-quantile plots of $-\log_{10}(p)$ values from the 15 compared methods when testing the causal effect for 1130 negative control trait pairs at different IV thresholds. The 15 compared methods include IVW (fixed), IVW (random), Egger, RAPS, Weighted-median, Weighted-mode, MR-PRESSO, MRMix, cML-MA, MR-Robust, MR-Lasso, MR-CUE, CAUSE, MRAPSS and MR-ConMix. Each distinct color on the plot represents the results at a specific IV threshold and the results at the default IV thresholds for MR-APSS and MR-CUE were set at 5×10^{-5} , while the default IV threshold for CAUSE was set at 1×10^{-3} . The remaining methods utilized a default IV threshold of 5×10^{-8} .



Figure 3: Evaluation of type I error control in confounding scenario (b) of pleiotropy. Type I error is evaluated by quantile-quantile plots of $-\log_{10}(p)$ values from the 15 compared methods when testing the causal effect for 77 negative control trait pairs at different IV thresholds. The 15 compared methods include IVW (fixed), IVW (random), Egger, RAPS, Weighted-median, Weighted-mode, MR-PRESSO, MRMix, cML-MA, MR-Robust, MR-Lasso, MR-CUE, CAUSE, MRAPSS and MR-ConMix. Each distinct color on the plot represents the results at a specific IV threshold and the results at the default IV thresholds of the compared MR methods are marked by a cross symbol. The default IV thresholds for MR-APSS and MR-CUE were set at 5×10^{-5} , while the default IV threshold for CAUSE was set at 1×10^{-3} .



Figure 4: Evaluation of Type I error control in the confounding scenario (c) of family-level confounders. Quantile-quantile (Q-Q) plots illustrating the $-\log_{10}(p)$ values for testing causal effects on 82 trait pairs using 15 different methods at their default IV thresholds. The comparison includes results from both population-based GWASs (depicted as red triangles) and sibling-based GWASs (depicted as green dots). The evaluated methods consist of IVW-fixed, IVW-random, Egger, RAPS, Weighted-median, Weighted-mode, MR-PRESSO, MRMix, cML-MA, MR-Robust, MR-Lasso, MR-CUE, CAUSE, MRAPSS, and MR-ConMix. MR-APSS and MR-CUE employ an IV threshold of 5×10^{-5} , CAUSE uses a threshold of 1×10^{-3} , while the remaining methods use a threshold of 5×10^{-8} .

221 Accuracy of causal effect estimates

To assess the accuracy of MR methods in estimating causal effects, we examined six pairs of 222 traits, where each pair involved the same trait being considered as both the "exposure" and 223 the "outcome" [16, 31]. In this specific scenario, the true causal effects for these trait pairs 224 were precisely known to be equal to one. This knowledge enabled us to compare the accuracy 225 of causal effect estimates given by different MR methods. We included three continuous traits: 226 Height, Waist Circumference (WC), and Educational Attainment (EA), as well as three binary 227 traits: Hypertension, High cholesterol, and Asthma. For each trait, we divided the UK Biobank 228 samples into two halves, representing the exposure GWAS and the outcome GWAS. We utilized 229 the Bolt-LMM software [32] to obtain GWAS summary statistics from these subsets. The 230 exposure GWAS summary statistics were used for both IV selection and causal effect estimation. 231

We varied the IV thresholds, starting with a stringent threshold of 5×10^{-8} , and progressively relaxed the thresholds to 5×10^{-7} , 5×10^{-6} , and 5×10^{-5} . As such, we can investigate the robustness of MR methods to weak IV bias and selection bias. However, it is important to note that in this analysis, we cannot assess the robustness of MR methods to pleiotropy or other forms of confounding when testing the effect of the trait on itself using data from the same population. The causal effect estimates and their confidence intervals for 15 MR methods at different IV thresholds are presented in Fig. 5.

Our study found that MR-APSS outperformed other MR methods and produced more 239 accurate causal effect estimates that were closer to the true value. Importantly, all of the 240 confidence intervals produced by MR-APSS at different IV thresholds covered the true value. 241 This indicates that MR-APSS is a promising method for accurately estimating causal effects in 242 MR analyses, robust to weak IV bias and selection bias. Furthermore, MR-APSS produces 243 narrower confidence intervals as the IV selection threshold was relaxed and weaker IVs were 244 included in the MR analysis. These findings highlight the potential advantages of including 245 more weak IVs in MR analysis to increase statistical power. Weighted-mode, at its default 246 IV threshold of 5×10^{-8} , delivered estimates comparable to those of MR-APSS in terms of 247 accuracy and coverage of true causal effects within the confidence intervals. Egger, while 248 producing larger estimation errors, provided unbiased estimates when a stringent IV threshold 249 was applied (5×10^{-8}) . However, it tended to overestimate causal effects when a looser IV 250 threshold was used. CAUSE, on the other hand, produced confidence intervals covering the 251 true causal effect only at a stringent threshold of 5×10^{-8} . 252

The majority of existing MR methods, including IVW (fixed), IVW (random), MR-Lasso, 253 cML-MA, MR-PRESSO, RAPS, Weighted-median, MR-Robust, MRMix, and MR-ConMix, 254 displayed limitations in estimation accuracy in the presence of weak IV bias and selection 255 bias. As the IV threshold became looser and weaker instruments were included, these methods 256 produced estimates that were biased toward the null effect. Moreover, their confidence intervals 257 failed to cover the true causal effects in most cases. This indicates that these methods are not 258 capable of dealing with weak IV bias and selection bias, which compromises the accuracy of 259 the causal effect estimates. It is crucial to acknowledge that the current strategy of using a 260 stringent IV threshold for IV selection, such as 5×10^{-8} , is not a foolproof solution to address 261 weak IV bias and selection bias. This approach has its limitations, including reduced power 262 due to a limited number of IVs and susceptibility to weak IV bias and selection bias even with 263 a stringent threshold. Our findings highlight the need for more robust MR methods that can 264 effectively handle weak instruments and mitigate selection bias to accurately estimate causal 265 effects. 266

In addition to biased causal effect estimation, methods such as MRMix and MR-Lasso have 267 their specific limitations. MRMix exhibited some instability when varying IV thresholds. For 268 instance, when examining the effect of height on itself, MRMix estimated the causal effect as 269 0 with a standard error of 0.015 using 302 IVs at a threshold of 5×10^{-8} . Similarly, at an 270 IV threshold of 5×10^{-6} with 666 IVs, MRMix again estimated the causal effect as 0 with 271 a standard error of 0.017. However, the estimation result by MRMix at an IV threshold of 272 5×10^{-7} was much more reliable. In this case, the causal effect of height on itself was estimated 273 as 0.93 with a standard error of 0.055, utilizing 517 IVs. MR-Lasso failed to report causal 274 estimates in some cases. For example, when testing the causal effect of WC on itself at the 275

²⁷⁶ IV threshold of 5×10^{-7} and that of EA on itself at the IV threshold of 5×10^{-6} , MR-Lasso ²⁷⁷ detected all IVs as invalid outliers and did not report any causal estimates.



Figure 5: Evaluation of the accuracy of causal effect estimation of 15 MR methods for six trait pairs. Each pair comprised the same trait as both the "exposure" and the "outcome" Analyzed traits include three continuous traits, i.e., Height, Waist Circumference (WC), and Educational Attainment (EA), and three binary traits, i.e., Hypertension, High cholesterol, and Asthma. The top panel shows the number of IVs selected using different IV thresholds with/without LD clumping. The bottom panel shows the point estimates and 95% confidence intervals of different methods at different IV thresholds for the three continuous traits (bottom left) and the three binary traits (bottom right). The vertical dashed gray line represents the true causal effect size 1. Each of the 15 MR methods is represented by a distinct color.

 $\xrightarrow{} LDL-C (n~20k) \rightarrow CAD \xrightarrow{} LDL-C (n~188k) \rightarrow CAD \xrightarrow{} LDL-C (n~843k) \rightarrow CAD$ Trait pair $\xrightarrow{} LDL-C (n~95k) \rightarrow CAD \xrightarrow{} LDL-C (n~343k) \rightarrow CAD \xrightarrow{} LDL-C (n~1,320k) \rightarrow CAD$

Threshold	IVW (fixed)	IVW (random)	MR-Lasso	cML-MA	MR-PRESSO	
	β [95% CI] P-value	β̂ [95% CI] P-value	β [95% CI] P-value	β [95% CI] P-value	β [95% CI] P-value	
5e-08 5e-07 5e-06 5e-05		↓ 4.12e-11 ↓ 2.29e-07 ↓ 2.54e-09 ↓ 1.79e-11	↓ 4.12e-11 ↓ 1.51e-22 ↓ 6.46e-24	1.16e-22 1.51e-23 1.10e-27 0.04e-17	↓↓ 4.02e-05 ↓↓ 9.75e-06 ↓↓ 6.96e-07 ↓↓ 5.56e-09	
5e-08 5e-07 5e-06 5e-05		4.45e-12 2.04e-08 1.19e-08 3.83e-10	→ 3.09e-35 → 3.19e-47 → 1.34e-42 → 2.04e-32	→ 1.53e-28 → 5.60e-35 → 3.77e-29 → 3.89e-30	↓↓ 4.66e-11 ↓↓ 7.82e-11 ↓↓ 3.83e-10 ↓↓ 2.73e-12	
5e-08 5e-07 5e-06 5e-05	↓ 2.19e-30 ↓ 3.08e-29 ↓ 3.69e-31 ↓ 7.73e-34	3.55e-09 9.43e-08 4.23e-09 5.74e-11	★ 8.97e-26 ★ 6.47e-28 ★ 3.14e-28 ★ 1.38e-31		8.76e-11 2.57e-13 3.31e-15 3.41e-17	
5e-08 5e-07 5e-06 5e-05		2.30e-08 1.57e-09 8.04e-11 •• 2.90e-11	→ 7.21e-39 → 3.72e-39 → 5.08e-39			
5e-08 5e-07 5e-06 5e-05	◆ 2.69e-59 ◆ 2.08e-60 ◆ 2.68e-61 ◆ 2.99e-57	→ 2.94e-19 → 9.95e-21 → 9.67e-24 → 9.48e-24				
5e-08 5e-07 5e-06	 ★ 7.89e-71 ◆ 1.53e-73 ◆ 2.06e-73 	1.54e-25 1.41e-28 6.00e-31				

Threshold	RAPS		Weighted-median		MR-Robust		MR-ConMix		MR-CUE	
	β̂ [95% CI] P-value	β [95% CI]	P-value	β [95% CI]	P-value	β̂ [95% CI]	P-value	β̂ [95% CI]	P-value
5e-08 5e-07 5e-06 5e-05	± ↓ ↓ ↓	9.15e-12 1.18e-07 1.95e-09 3.82e-10	± ₽ ₽	9.33e-12 1.22e-10 4.53e-11 1.74e-07	∔+ +	8.69e-10 2.89e-08 2.77e-09 5.37e-07	Į+Į	2.01e-08 5.40e-07 9.25e-07 1.02e-03		1.69e-18 2.12e-11 6.76e-16 3.78e-18
5e-08 5e-07 5e-06 5e-05		2.25e-13 4.90e-51 1.58e-53 7.66e-51		9.02e-18 4.85e-04 0.161 0.062		2.56e-15 9.02e-16 7.14e-07 4.52e-04	+++	1.64e-10 1.92e-13 5.44e-13 1.42e-09	*	8.90e-24 2.26e-30 5.69e-35 1.08e-35
5e-08 5e-07 5e-06 5e-05	++++	2.65e-10 8.76e-10 1.41e-11 2.18e-13	++++	2.09e-10 3.70e-12 3.74e-11 1.22e-10		1.59e-10 7.73e-11 2.12e-12 2.43e-13	HH.	1.85e-09 1.53e-10 6.59e-11 6.44e-11	••• •• ••	5.37e-22 7.65e-17 1.39e-17 2.42e-24
5e-08 5e-07 5e-06 5e-05	++++	3.90e-13 4.30e-15 1.39e-16 4.87e-17	t t t	8.64e-20 4.99e-15 1.00e-15 8.00e-14	+++ ++	6.02e-16 1.40e-17 2.19e-18 5.49e-17	+++	1.85e-14 1.18e-13 3.40e-14 7.94e-13	141 141 141	7.15e-31 6.49e-29 2.89e-36 1.74e-30
5e-08 5e-07 5e-06 5e-05	141 141 141	1.80e-29 3.53e-32 4.74e-35 2.18e-36		4.47e-26 1.16e-25 7.21e-26 1.56e-24		5.78e-38 3.57e-40 1.09e-40 1.33e-40		3.79e-27 1.81e-28 7.97e-29 7.48e-30	14-1 14-1 14-1 14-1	1.16e-56 1.83e-47 1.47e-53 2.04e-50
5e-08 5e-07 5e-06 5e-05		2.96e-37 5.63e-41 5.19e-42 2.47e-44	+++	1.98e-25 1.96e-26 1.82e-26 4.39e-26		2.45e-39 2.50e-41 1.22e-40 2.03e-40		8.93e-32 1.59e-33 1.26e-33 1.31e-35		3.01e-59 1.08e-70 8.33e-60 1.51e-65

	MR-APSS		CAUSE		MRMix		Egger	Egger		Weighted-mode	
Threshold	β̂ [95% CI]	P-value	β̂ [95% CI]	P-value	β̂ [95% CI]	P-value	β̂ [95% CI]	P-value	β̂ [95% CI]	P-value	
5e-08 5e-07 5e-06 5e-05 1e-03	HH	2.71e-05 2.63e-05 2.46e-06 5.10e-08	[⊥] ↓ ↓ ↓	2.04e-04 0.010 5.72e-03 7.15e-03 0.031	↓ ↓ ↓	3.13e-11 2.06e-06 0.011 0.204		0.894 0.077 0.011 2.51e-06	↓ ↓ ↓	4.28e-03 1.57e-03 7.09e-04 0.142	
5e-08 5e-07 5e-06 5e-05 1e-03	++++	1.05e-11 5.00e-14 8.62e-16 3.31e-16		6.28e-03 9.89e-03 3.43e-03 3.25e-03 2.19e-03		1.55e-05 4.05e-08 1.57e-09 3.93e-12		2.19e-03 0.426 0.576 0.223		9.27e-06 0.499 0.655 0.538	
5e-08 5e-07 5e-06 5e-05 1e-03	ŧŧŧ	3.80e-12 3.02e-11 6.85e-12 1.78e-13	++++	0.011 0.013 0.010 0.011 3.43e-03		0.036 5.75e-04 5.74e-06 1.88e-05		0.018 6.38e-03 2.61e-03 7.47e-04		0.082 0.067 0.051 0.040	
5e-08 5e-07 5e-06 5e-05 1e-03		1.23e-09 6.36e-10 5.31e-11 1.51e-10	++++	9.84e-03 7.06e-03 6.09e-03 0.011 0.022	++++	3.84e-08 8.40e-10 1.66e-10 1.23e-12		3.57e-04 1.06e-04 2.34e-05 1.60e-08		2.39e-07 2.01e-07 8.56e-08 2.75e-08	
5e-08 5e-07 5e-06 5e-05 1e-03	ŧ	6.80e-19 1.78e-18 1.57e-19 4.24e-18	++++	3.78e-05 2.80e-05 5.46e-05 1.51e-04 1.83e-04		2.57e-25 2.60e-27 6.56e-30 1.43e-32		2.83e-05 1.48e-06 8.29e-09 1.07e-12		9.25e-13 1.48e-13 2.55e-15 4.48e-13	
5e-08 5e-07 5e-06 5e-05 1e-03	++++	4.92e-22 1.56e-23 8.00e-25 1.41e-25	++++	2.61e-04 3.25e-04 3.13e-04 6.33e-04 2.71e-04	÷	4.54e-35 3.14e-35 1.27e-28 4.43e-30	++++	5.32e-07 3.06e-08 2.90e-11 2.17e-15	ŦŦŦ	5.75e-12 2.59e-12 3.11e-13 9.73e-15	

Figure 6: MR analysis results of LDL-C and CAD from 15 MR methods at different IV thresholds. Six GWAS datasets for LDL-C were used, each represented by a distinct color. The vertical dashed gray line represents the zero causal effect size. Compared methods include IVW-fixed, IVW-random, Egger, RAPS, Weighted-median, Weighted-mode, MR-PRESSO, MRMix, cML-MA, MR-Robust, MR-Lasso, MR-CUE, CAUSE, MRAPSS and MR-ConMix represented by different colors. The IV threshold is varied from 5×10^{-5} , 5×10^{-6} , 5×10^{-7} and 5×10^{-8} . The result of CAUSE at its default IV threshold 1×10^{-3} is also presented.

²⁷⁸ Replicability and power

To assess the replicability and power of the MR methods, we applied all the compared methods 279 to infer the causal effect between LDL-C and CAD using six LDL-C GWAS datasets collected 280 from five separate studies. By comparing the causal effects estimated from different GWAS 281 datasets of the same trait, we were able to assess the reliability and generalizability of their 282 causal effect estimates across different study designs and sample sizes. We also considered the 283 IV thresholds varied from the stringent 5×10^{-8} to the relaxed 5×10^{-7} , 5×10^{-6} , and 5×10^{-5} 284 to examine the sensitivity of the methods to different levels of instrument strength. The causal 285 effect estimates, their 95% confidence intervals, and p-values produced by each method for 286 different datasets and different IV thresholds are shown in Fig. 6. 287

Among all the compared methods, CAUSE and MR-APSS achieved outstanding performance 288 in terms of replicability. Both CAUSE and MR-APSS are capable of producing confidence 289 intervals that reject the null causal effect. The causal effect estimates and confidence intervals 290 produced by both methods were highly consistent across different studies and different IV 291 thresholds. The high consistency and generalizability of the results produced by these methods 292 are particularly noteworthy, as they suggest that the causal effect estimates obtained using 293 CAUSE and MR-APSS are likely to be more accurate and reliable than those obtained using 294 other methods. However, we note that the *p*-values produced by CAUSE do not agree well with 295 its confidence intervals. Consistent with previous results, the *p*-values produced by CAUSE are 296 likely to be deflated. Therefore, caution should be exercised when interpreting the *p*-values 297 produced by CAUSE. 298

Most of the MR methods we compared detected a significant causal relationship for 299 all 24 tests between LDL-C and CAD using six datasets of LDL-C at four different IV 300 thresholds. However, Egger, Weighted-mode, Weighted-median, and MRMix were unable to 301 detect significant causal relationships in some cases. Specifically, among the 24 tests, Egger, 302 Weighted-mode, Weighted-median, and MRMix failed to detect significant causal effects for 303 five, four, two, and one test between LDL-C and CAD at the nominal level of 0.05, respectively. 304 Although Egger and Weighted-mode showed good performance in terms of type I error control, 305 our analysis revealed that Egger tended to produce estimates with large estimation errors, and 306 Weighted-mode may have low power. Moreover, Weighted-median and MRMix, which are likely 307 to produce false positives as shown in our previous analysis, can also lead to causal effects being 308 wrongly shrunk to zero in some cases. However, we found that all methods, including Egger, 309 Weighted-mode, Weighted-median, and MRMix, were able to detect significant causal effects 310 in the cases of LDL-C($n \sim 843k$) and LDL-C($n \sim 1, 320k$), indicating improved performance 311 with large sample sizes. This suggests that larger sample sizes may lead to more accurate and 312 reliable causal inference in MR analyses. 313

³¹⁴ Consistent with previous findings, our analysis showed that most MR methods produced ³¹⁵ causal effect estimates that were sensitive to the choice of IV thresholds. Specifically, we found ³¹⁶ that causal effect estimates produced by most MR methods were closer to zero at a looser ³¹⁷ IV threshold of 5×10^{-5} compared to a more stringent IV threshold of 5×10^{-8} . However, ³¹⁸ we observed better consistency in the causal estimates produced by the MR methods across ³¹⁹ IV thresholds for the cases of LDL-C($n \sim 843k$) and LDL-C($n \sim 1, 320k$). Importantly, as ³²⁰ GWAS sample sizes increase to the scale of millions, the influence of weak IV bias and selection

³²¹ bias may be greatly alleviated. Our analysis highlights the potential benefits of larger sample
³²² sizes for improving the accuracy and reliability of MR analyses. Therefore, researchers should
³²³ consider using larger sample sizes in MR studies to improve the robustness of their causal
³²⁴ inference.

325 Discussion

We present a benchmarking study of 15 two-sample summary-level data-based MR methods 326 for causal inference. Our evaluation focuses on three crucial aspects: type I error control 327 in the presence of various confounding scenarios (e.g., population stratification, pleiotropy, 328 and assortative mating), the accuracy of causal effect estimates, replicability and power. 329 Additionally, we explored the robustness of MR methods by evaluating their performance across 330 a range of IV thresholds, assessing their ability to handle invalid IVs, and their sensitivity to 331 IV selection. What sets our study apart is that our benchmark study is based on real-world 332 datasets. Rather than relying on simulated or synthetic data, we carefully curated five diverse 333 genetic datasets containing over one thousand trait pairs. The utilization of real-world datasets 334 provides a more realistic and comprehensive evaluation of the performance of MR methods in 335 practical scenarios. 336

Through the innovative designs of experiments that include a wide range of scenarios 337 using real-world datasets, our study revealed that the performance of MR methods depends 338 on underlying confounding factors that are very prevalent in real-world scenarios. Among 339 the methods analyzed, Egger, weighted mode, and MR-APSS consistently demonstrated 340 effective control of type I error across all three datasets representing different confounding 341 scenarios, including population stratification, pleiotropy, and family-level confounders. However, 342 CAUSE failed to control type I error using its default IV threshold of 1×10^{-3} in the 343 presence of strong population stratification, although it exhibited deflation in other confounding 344 scenarios. The remaining 11 MR methods displayed varying performances across the datasets 345 representing different confounding scenarios. In the dataset representing strong population 346 stratification (confounding scenario a), all 11 methods exhibited significant inflation of type 347 I error. Conversely, in the datasets representing confounding scenarios of pleiotropy and 348 family-level confounders (scenarios b and c), some methods, such as IVW (random), MR-Lasso. 349 MR-PRESSO, RAPS, Weighted-median, IVW (fixed), cML-MA, MR-ConMix, and MR-Robust, 350 demonstrated less severe inflation. Notably, MRMix displayed effective control of type I error 351 in the dataset representing family-level confounders (confounding scenario c) but exhibited 352 inflation in the dataset representing population stratification (confounding scenario a) and 353 pleiotropy (confounding scenario b). These findings underscore the necessity of considering 354 the characteristics of the datasets when selecting an appropriate MR method for analysis. 355 Researchers should carefully assess the specific confounding factors present in their data and 356 choose a method that has demonstrated robustness in handling those confounders. 357

Our study emphasized the significant impact of IV selection on the performance of MR methods. We found that using a looser threshold for IV selection resulted in inflated type I errors and increased bias in causal effect estimates for most methods. This highlights the limitations of certain MR methods in handling invalid or weak IVs and emphasizes the need to mitigate the potential bias associated with IV selection.

Based on our findings, we put forward the following recommendations as guidelines for best 363 practices, aiming to assist researchers in choosing the most suitable summary-level MR methods 364 for studying causal relationships between specific exposure-outcome trait pairs. By adhering 365 to these guidelines, researchers can enhance the reliability and validity of their MR analyses. 366 Firstly, we recommend conducting an analysis using negative controls. By incorporating 367 negative controls, such as using hair colors as negative control outcomes, researchers can 368 detect the presence of confounding bias and evaluate the robustness of different methods to 369 confounding. This helps in selecting methods that can effectively handle confounding and 370 provide more reliable results. Secondly, we advocate for adopting multiple standards for IV 371 selection. Instead of relying solely on a single *p*-value threshold, researchers should consider 372 various criteria and adjust the threshold accordingly to select IVs. By employing multiple 373 standards, researchers can assess the sensitivity of MR methods to IV selection and invalid IVs. 374 This allows for a more thorough evaluation of the methods' performance and helps prioritize 375 methods that are robust to IV selection. Lastly, whenever feasible, we encourage researchers 376 to gather data from multiple independent sources for the exposure and outcome of interest. 377 This could involve incorporating data from different study populations, cohorts, or databases. 378 By considering data from diverse sources, researchers can prioritize methods that demonstrate 379 high replicability across multiple sources. This increases the reliability of the findings and 380 strengthens the credibility of the robustness of the selected MR method. 381

While our benchmark study provides valuable insights into the performance of summary-382 level MR methods, it does have certain limitations. Firstly, the selection and measurement of 383 confounding factors in real-world datasets can be a challenging task. Although we made careful 384 efforts to include datasets that represented specific confounding scenarios, it is important to 385 recognize that different types of confounders may coexist in these datasets. Secondly, due 386 to the difficulty in collecting true positive cases from real data, we assessed the estimation 387 accuracy of causal effect by treating the same trait as both exposure and outcome and examined 388 replicability with a case study by employing multiple GWASs of the same exposure trait. While 389 these strategies indirectly reflect the performance of MR methods in terms of power, a more 390 comprehensive power analysis using multiple positive cases would provide valuable insights into 391 the methods' ability to detect causal effects under different conditions. Thirdly, our evaluation 392 of the estimation accuracy of MR methods utilized trait pairs where the exposure and outcome 393 were the same trait. This design choice is currently the only possible way to ensure the true 394 causal effects between trait pairs are known. However, we have to admit that the downside of 395 this design is that this example does not test the methods' robustness to confounding factors 396 like pleiotropy because the exposure and outcome are the same traits. Lastly, our benchmark 397 study focused solely on summary-level MR methods, but it is important to recognize the 398 availability of individual-level MR methods such as GENIUS[33] and GENIUS-MAWII [34] and 399 MR-MiSTERI [35]. Although these methods are beyond the scope of our study, researchers 400 should consider exploring them when they align with the study design and data availability, as 401 they may provide additional insights and benefits in specific research contexts. 402

$_{403}$ Methods

⁴⁰⁴ Datasets for evaluation of type I error control in different confounding ⁴⁰⁵ scenarios

406 Confounding scenario (a): Population stratification

We aim to assess the effectiveness of MR methods in controlling type I errors in the presence of 407 population stratification. To achieve this, we chose four hair color-related traits (Hair color: 408 black, Hair color: blonde, Hair color: light brown, Hair color: dark brown) and skin tanning 409 ability (Tanning) as our negative control outcomes. The GWAS summary statistics for the 410 negative control outcomes were obtained from the GWAS ATLAS resource [30], which contains 411 GWAS data from 600 traits in the UK Biobank. These traits were selected based on their 412 characteristics: they are primarily determined at birth and thus are unlikely to be influenced 413 by traits occurring after birth, and they are susceptible to confounding due to population 414 stratification as indicated by LDSC intercept values of 1.678 (se = 0.017) for Hair color: black, 415 1.206 (se = 0.016) for Hair color: blonde, 1.335 (se = 0.013) for Hair color: light brown, 1.510416 (se = 0.018) for Hair color: dark brown, and 1.916 (se = 0.020) for Tanning. 417

Next, we focused on selecting suitable exposure traits from the remaining 555 traits available in the GWAS ATLAS. We applied specific criteria to identify traits that were unrelated to hair or skin, had LDSC heritability estimates greater than 0.01, and possessed a minimum of four IVs. Through this process, we identified 226 traits that met these criteria, which we then utilized as exposure traits in our MR analysis.

We then applied MR methods to the 1130 exposure-outcome trait pairs formed by the selected exposure and negative control outcome traits (Supplementary data 1) and evaluated the effectiveness of MR methods in controlling for type I errors in the presence of population stratification.

427 Confounding scenario (b): Pleiotropy

We aim to assess the type I error control of MR methods in the presence of confounding factors, 428 such as pleiotropy, which can induce genetic correlation between trait pairs that are not causally 429 linked. To accomplish this, we analyzed trait pairs consisting of 11 exposures and seven negative 430 control outcomes. The selected exposures included five adult behavior-related traits, namely 431 Coffee consumption [36], Instant coffee consumption [36], Ground coffee consumption [36], 432 automobile speeding propensity [37] and risk [37], as well as six aging-related traits, including 433 Self-rated health (http://www.nealelab.is/uk-biobank/, Phenotype Code: 2178), Longevity 434 [38], Parental lifespan [39], Health span [40], Perceived age [41], and Frailty Index [42]. On the 435 other hand, the negative control outcomes comprised seven childhood-related traits, such as 436 Childhood aggression [43], Childhood BMI [44], Childhood intelligence [45], Fetal birth weight 437 [46], Maternal birth weight [46], Pubertal growth (a single height measurement at age 10 in 438 girls and 12 in boys) [47], and Comparative body size at age 10 [30]. We chose negative control 439 outcomes based on the convention that traits developed after adulthood are unlikely to affect 440 traits developed before adulthood causally. Consequently, causal effects between the selected 441 exposures and negative control outcomes were considered implausible. 442

To conduct our analysis, we collected GWAS summary statistics for the exposure and 443 outcome traits from multiple GWAS sources (detailed information can be found in Supplementary 444 data 2). Subsequently, we examined the LDSC intercept estimates of the outcomes and 445 calculated the genetic correlation estimates between the trait pairs (see SFig. S4). The LDSC 446 intercepts for the outcomes were found to be approximately one, suggesting that population 447 stratification was not a prominent confounding factor among these trait pairs. Out of the 77 448 trait pairs analyzed, 49 pairs exhibited significant genetic correlations at the nominal level of 449 0.05. These analyses allowed us to evaluate the performance of the MR methods in the presence 450 of pleiotropy or other types of confounding that could induce genetic correlation between trait 451 pairs. By considering these factors, we gained valuable insights into how well the MR methods 452 controlled type I errors in the presence of confounders, thereby enhancing our understanding of 453 their performance in such scenarios. 454

455 Confounding scenario (c): Family-level confounders

To assess the type I error control of MR methods in the presence of family-level confounders like 456 assortative mating or other indirect genetic effects, we conducted an analysis using summary 457 data obtained from a recent within-sibship GWAS study [30]. This dataset provided summary 458 statistics for 25 traits, encompassing both within-sibship and population-based GWAS estimates. 459 Details on these GWASs are summarized in Supplementary data 3. To ensure that the trait 460 pairs analyzed in our study were suitable for evaluating type I errors, we required them to be 461 genetically uncorrelated. This criterion was established to ensure that pairs with zero genetic 462 correlation are unlikely to be causally linked, indicating the absence of a causal effect. To 463 achieve this, we utilized LDSC [48] to estimate the genetic correlation between trait pairs 464 among the 25 phenotypes using both population-based GWAS and within-sibship GWAS. Our 465 selection process involved identifying 82 trait pairs (Supplementary data 3) with insignificant 466 genetic correlation at the nominal level of 0.05 in both types of GWAS analyses. Subsequently, 467 we applied MR methods to these selected trait pairs using both population-based GWAS and 468 within-sibship GWAS. By comparing the results obtained from each method based on the two 469 types of GWAS designs, we were able to examine the ability of MR methods to control for the 470 effects of family-level confounders. 471

472 Datasets for evaluation of the accuracy of causal effect estimates

To evaluate the accuracy of the causal effect estimates of each method, we consider a special 473 setting where the exposure and outcome are the same traits. Under a linear model setting, 474 the genetic effects of IVs on the exposure and the outcome are the same but the effect size 475 estimates are different. Therefore, there is no pleiotropy or other forms of confounding, and we 476 could expect the true causal effect known to be exactly one [16, 31, 49]. Specifically, we used 477 six traits in this setting including three continuous traits, i.e. Height, Waist Circumference 478 (WC), and Educational attainment (EA), and three binary traits, i.e. Hypertension, High 479 cholesterol, and Asthma. To obtain the exposure GWAS and outcome GWAS, we split the UK 480 Biobank samples into two halves. One half was used as the exposure GWAS and the other 481 half was used as the outcome GWAS. The sample sizes of the GWASs ranged from 121,194 to 482 168.300 (see details in supplementary data 4). The GWAS summary statistics are obtained 483

using the BOLT-LMM software [50]. In our analysis, GWAS estimates for the binary traits are
also obtained using linear models through BOLT-LMM and are then used as input for MR
analysis. We could thus expect the true causal effect between the same binary exposure and
binary outcome also equal one.

488 Datasets for evaluation of replicability and power

We used the example of low-density lipoprotein cholesterol (LDL-C) and coronary artery disease 489 (CAD) for evaluation of the replicability and power of MR methods. The use of the LDL-C and 490 CAD example in our case study provides several benefits. First, it serves as a positive control for 491 comparing the performance of MR methods. High-level LDL-C is a well-established important 492 risk factor for CAD. Several randomized control trials have consistently shown that lowering 493 LDL-C levels with stating is effective in the prevention of CAD [51, 52, 53, 54, 55, 56, 57]. This 494 allows us to evaluate the accuracy and replicability of different MR methods in a setting where 495 we have high confidence in the existence of the positive causal effect. Second, the availability 496 of multiple GWAS summary datasets for LDL-C provides a rich source of data for evaluating 497 the performance of MR methods. We can thus assess the replicability of different MR methods 498 using datasets with varying sample sizes and study designs. In our analysis, we gathered six 499 European ancestries GWAS summary datasets for LDL-C i.e., LDL-C $(n \sim 20k)$ [58], LDL-C 500 $(n \sim 95k)$ [59], LDL-C $(n \sim 188k)$ [60], LDL-C $(n \sim 343k)$ by the Neale Lab, LDL-C $(n \sim 843k)$ 501 (without UK biobank samples) and LDL-C($n \sim 1, 320$ k) (with UK biobank samples) [61]. The 502 GWAS sample size increased from 19.840 in 2009 to 1.35 million in 2022. We used the same 503 outcome GWAS for CAD which was obtained from the CARDIoGRAMplusC4D Consortium 504 [62]. More details for the GWAS sources can be found in Supplementary data 5. 505

506 Steps of running MR methods

507 Step 1: quality control of GWAS summary statistics

The aim of the quality control step is to identify a candidate set of SNPs with high quality for IV selection and MR analysis. In our analysis, we adopted several common QC measures for GWAS summary statistics, including

- Checking missingness. For each SNP, the required data information for performing MR analysis includes SNP identifier (we use rs number), effect allele, none effect allele, effect size, standard error, sample size (N), and p-value. SNPs missing any of the required information should be removed.
- Checking duplicates. Duplicated SNPs are SNPs with the same SNP identifier. We removed SNPs with duplicates to avoid any potential errors.
- Keeping unambiguous SNPs. We only involved unambiguous SNPs in our analysis, i.e.,
 SNPs with the allele types A/G, A/C, T/G, or T/C.
- Removing poorly imputed SNPs. The imputed information score (Info) is a measure of the quality of the imputed SNPs. SNPs with Info < 0.9 are likely to be poorly imputed

- and were excluded from analysis. This QC step is applicable as long as the imputed information is available in GWAS summary statistics.
- Removing low minor allele frequency (MAF) SNPs. Low MAF SNPs are those with MAF
 below a certain threshold (e.g., 0.01 or 0.05). SNPs with low MAF were excluded from
 analysis as they are more prone to error. The QC threshold for MAF was chosen as 0.01
 in our analyses. We will show later that the MR analysis results from different methods
 are not sensitive to the QC threshold for MAF. This QC step is applicable as long as
 MAF is available in GWAS summary statistics.
- Keeping SNPs in the set of HapMap 3 list. Because MAF or imputed information may be missing from the GWAS summary statistics, like LDSC, we restricted the analysis to a set of common and well-imputed SNPs in the HapMap 3 reference panel.
- Removing SNPs in the complex Major Histocompatibility Region (Chromosome 6, 26Mb - 34Mb).
- Removing SNPs with extremely large χ^2 . We removed SNPs with $\chi^2 > max\{80, N/1000\}$ to reduce the undue influence of outliers on MR analysis results

After the QC step, GWAS datasets were formatted by retaining only the necessary data information for a set of SNPs that meet pre-determined quality control criteria. The retained data information typically includes the rs number, effect allele, non-effect allele, effect size, standard error, and *p*-value. It is important to note that we assume the phenotype and genotypes in GWASs are scaled to have a mean of zero and a variance of one. This scaling allows for the effect size and standard error to be calculated from *z*-scores and sample size, which can be more easily obtained from GWAS summary statistics.

The QC step is also important for methods like MR-APSS and CAUSE, which use SNPs across the genome to estimate nuisance parameters for their model.

⁵⁴⁵ Step 2: harmonizing SNP effects of the exposure and outcome

Performing MR analysis for an exposure-outcome trait pair requires harmonizing the effect 546 estimates of each SNP to refer to the same allele. This is crucial for accurate MR analysis, as it 547 ensures that the effect estimates for each SNP are comparable and can be combined to estimate 548 the causal effect of the exposure on the outcome. To achieve this, we first checked the strands 549 of the exposure and outcome alleles and flipped the outcome allele to the same strand as the 550 exposure allele if they differ. We then checked the effect alleles of the exposure and outcome, 551 and if they differed, we flipped the direction of the SNP-outcome effect to ensure that all effect 552 estimates were aligned to the same allele. For example, if an SNP had an effect/non-effect 553 allele of A/G in the exposure GWAS and C/T in the outcome GWAS, we first flipped the 554 outcome allele to G/A. As the outcome GWAS presents the effect for the non-effect allele in 555 the exposure GWAS, we then flipped the direction of the outcome effect to its opposite. Note 556 that only unambiguous SNPs with allele types A/G, A/C, T/G, or T/C were considered, and 557 any ambiguous SNPs were discarded from the analysis. 558

559 Step 3: IV selection and extract IV effects

After obtaining the harmonized summary dataset for each exposure-outcome trait pair, we 560 began selecting instrumental variables (IVs) by identifying SNPs that were reliably associated 561 with the exposure trait using a p-value threshold. To examine the robustness of MR methods 562 to weak IV bias, we varied the *p*-value threshold for IV selection from 5×10^{-8} to 5×10^{-5} . For 563 those methods that require independence, we further used the Plink LD clumping procedure 564 with a threshold of $r^2 = 0.001$ and a window size of 1 Mb to obtain a set of nearly independent 565 SNPs from the initial set of SNPs that passed the p-value threshold. It is important to note 566 that we required each trait pair to be analyzed with a minimum of five IVs. The final dataset 567 containing the summary data for the selected IV set was used as input for performing MR 568 analysis, with the goal of estimating the causal effect of the exposure on the outcome. 569

While it is common practice to select independent IVs from the exposure dataset and obtain summary data from the outcome GWAS, we perform IV selection after harmonizing the exposure and outcome datasets. This approach may reduce IV loss due to LD clumping, as selected IVs may be absent from the outcome GWAS.

574 Step 4: run MR methods

⁵⁷⁵ The implementation details of the 15 compared methods are described as follows:

IVW-fixed, IVW-random, Egger, Weighted-median, and Weighted-mode were performed using the legacy version of the TwoSampleMR R package with default options (https://github.com/MRCIEU/TwoSampleMR).

- RAPS wass performed using the mr.raps package without diagnostics by setting diagnostics=F.
- MRMix was performed using the MRMix package with defalut option (https://github. com/gqi/MRMix).
- MR-PRESSO was performed using the MRPRESSO package (https://github.com/ rondolab/MR-PRESSO) using OUTLIERtest = TRUE, DISTORTIONtest = TRUE, SignifThreshold = 0.05, seed = 1234, and NbDistribution = 1000 options.
- MR-Robust was performed with *lmrob* in robustbase R package.

• MR-Lasso and MR-ConMix are performed using the *mr_lasso* and *mr_conmix* functions, respectively, with their default options in MendelianRandomization R package.

- cML-MA wad performed using R function of $mr_c cML$ with default options in the MRcML R package. It is important to note that we did not compare the results of the Data perturbation (DP) versions of cML-MA in our analysis. This decision was based on the consideration that the default cML-MA version (without DP) is more time-efficient.
- MR-APSS was performed using the MR-APSS (https://github.com/YangLabHKUST/ MR-APSS) R package.
- CAUSE was performed using the CAUSE (https://github.com/jean997/cause) R package.

• MR-CUE was performed using the MR.CUE (https://github.com/QingCheng0218/MR. 597 CUE) R package.

⁵⁹⁸ The choice of minor allele frequency threshold in quality control step

One of the QC measures for GWAS summary statistics was to exclude low MAF SNPs with 599 the concern that they are more prone to error. Typically, studies use MAF thresholds of 0.01 600 or 0.05. To assess the impact of the MAF threshold and to determine an appropriate MAF 601 threshold for MR, we conducted an analysis to explore the effect of the MAF threshold by 602 varying the MAF threshold. Specifically, we considered the analysis of the six UK Biobank 603 trait pairs used to evaluate causal effect estimation. We used MAF thresholds of 0.01 and 0.05 604 in the QC step for the summary statistics, and we then applied MR methods to the formatted 605 summary datasets with different MAF QC thresholds. Results from different MR methods 606 using different MAF thresholds are given in Sfig. S2. Our analysis shows that MR methods are 607 generally not sensitive to the choice of MAF thresholds. However, to obtain more candidate 608 IVs, we chose a threshold of 0.01 for MAF QC in our MR analysis. 609

⁶¹⁰ The choice of reference panel for LD clumping

All of the compared MR methods, except for MR-CUE, require independent or weakly correlated 611 IVs. For those methods, an LD reference panel was used to perform LD clumping in the IV 612 selection step. In contrast, MR-CUE allows for correlated IVs, and an LD reference panel is 613 used to model the correlation between SNPs. To examine whether MR methods are sensitive to 614 the choice of LD reference panel, we conducted a sensitivity analysis by comparing the results 615 obtained using different reference panels. Specifically, we used an in-sample UK Biobank LD 616 reference panel and the 1000 Genomes reference panel of European ancestry for the six UK 617 Biobank trait pairs used to evaluate causal effect estimation. Both reference panels are of the 618 same ancestry as the study population. We present the results from different MR methods 619 using different LD reference panels in Supplementary Figure Sfig. S3. Our analysis shows that 620 MR methods are generally not sensitive to the choice of LD reference panel as long as the 621 panels are from the same ancestry. 622

Data availability

The UK Biobank data are from UK Biobank resources under application number 30186. All GWAS summary statistics used in this study are downloadable at https://github.com/ YangLabHKUST/MRbenchmarking. Supplementary Data 1-3, and 5 provide the references of these datasets.

628 Code availability

The source codes to reproduce all the analyses can be accessed at the following location: https://github.com/YangLabHKUST/MRbenchmarking.

631 Acknowledgements

We acknowledge the following grants: Hong Kong Research Grant Council grants nos. 16301419,
16308120, 16307221 and 16307322, Hong Kong University of Science and Technology Startup
Grants R9405 and Z0428 from the Big Data Institute, Guangdong-Hong Kong-Macao Joint
Laboratory grant no. 2020B1212030001 and the RGC Collaborative Research Fund grant no.
C6021-19EF to C.Y., City University of Hong Kong Startup Grant 7200746 and Strategic
Research Grant 21300423 to M.C.

References

- [1] Lars Bondemark and Sabine Ruf. Randomized controlled trial: the gold standard or an
 unobtainable fallacy? *European Journal of Orthodontics*, 37(5):457–461, 2015.
- [2] Vanessa Didelez and Nuala Sheehan. Mendelian randomization as an instrumental variable
 approach to causal inference. Statistical methods in medical research, 16(4):309–330, 2007.
- [3] George Davey Smith and Gibran Hemani. Mendelian randomization: genetic anchors for
 causal inference in epidemiological studies. *Human Molecular Genetics*, 23, 2014.
- [4] Kaitlin H Wade, James Yarmolinsky, Edward Giovannucci, Sarah J Lewis, Iona Y Millwood,
 Marcus R Munafò, Fleur Meddens, Kimberley Burrows, Joshua A Bell, Neil M Davies,
 et al. Applying mendelian randomization to appraise causality in relationships between
 nutrition and cancer. *Cancer Causes & Control*, 33(5):631–652, 2022.
- [5] Jean-Baptiste Pingault, Paul F O'reilly, Tabea Schoeler, George B Ploubidis, Frühling
 Rijsdijk, and Frank Dudbridge. Using genetic data to strengthen causal inference in
 observational research. *Nature Reviews Genetics*, 19(9):566–580, 2018.
- [6] Stephen Burgess, Amy M Mason, Andrew J Grant, Eric AW Slob, Apostolos Gkatzionis,
 Verena Zuber, Ashish Patel, Haodong Tian, Cunhao Liu, William G Haynes, et al. Using
 genetic association data to guide drug discovery and development: Review of methods
 and applications. *The American Journal of Human Genetics*, 110(2):195–214, 2023.

[7] Amand F Schmidt, Chris Finan, Maria Gordillo-Marañón, Folkert W Asselbergs, Daniel F
 Freitag, Riyaz S Patel, Benoît Tyl, Sandesh Chopade, Rupert Faraway, Magdalena
 Zwierzyna, et al. Genetic drug target validation using mendelian randomisation. Nature
 communications, 11(1):3255, 2020.

- [8] Debbie A Lawlor, Roger M Harbord, Jonathan AC Sterne, Nic Timpson, and George
 Davey Smith. Mendelian randomization: using genes as instruments for making causal
 inferences in epidemiology. *Statistics in medicine*, 27(8):1133–1163, 2008.
- [9] Vanessa Didelez, Sha Meng, and Nuala A. Sheehan. Assumptions of IV Methods for
 Observational Epidemiology. *Statistical Science*, 25(1):22 40, 2010.

- [10] Marie Verbanck, Chia-Yen Chen, Benjamin Neale, and Ron Do. Detection of widespread
 horizontal pleiotropy in causal relationships inferred from Mendelian randomization between
 complex traits and diseases. *Nature genetics*, 50(5):693, 2018.
- [11] Haoran Xue, Xiaotong Shen, and Wei Pan. Constrained maximum likelihood-based
 Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects.
 The American Journal of Human Genetics, 108(7):1251–1269, 2021.
- [12] Jessica MB Rees, Angela M Wood, Frank Dudbridge, and Stephen Burgess. Robust
 methods in mendelian randomization via penalization of heterogeneous causal estimates.
 PloS one, 14(9):e0222362, 2019.
- [13] Jack Bowden, George Davey Smith, Philip C Haycock, and Stephen Burgess. Consistent
 estimation in mendelian randomization with some invalid instruments using a weighted
 median estimator. *Genetic epidemiology*, 40(4):304–314, 2016.

[14] Fernando Pires Hartwig, George Davey Smith, and Jack Bowden. Robust inference
 in summary data mendelian randomization via the zero modal pleiotropy assumption.
 International journal of epidemiology, 46(6):1985–1998, 2017.

- [15] Jack Bowden, George Davey Smith, and Stephen Burgess. Mendelian randomization
 with invalid instruments: effect estimation and bias detection through Egger regression.
 International journal of epidemiology, 44(2):512–525, 2015.
- [16] Qingyuan Zhao, Jingshu Wang, Gibran Hemani, Jack Bowden, and Dylan S Small.
 Statistical inference in two-sample summary-data mendelian randomization using robust
 adjusted profile score. *The Annals of Statistics*, 48(3):1742–1769, 2020.
- [17] Jia Zhao, Jingsi Ming, Xianghong Hu, Jin Liu, and Can Yang. Bayesian Weighted
 Mendelian Randomization for Causal Inference based on Summary Statistics. arXiv
 preprint arXiv:1811.10223, 2018.
- [18] Jean Morrison, Nicholas Knoblauch, Joseph H. Marcus, Matthew Stephens, and Xin He.
 Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects
 using genome-wide summary statistics. *Nature Genetics*, 2020.
- [19] Xianghong Hu, Jia Zhao, Zhixiang Lin, Yang Wang, Heng Peng, Hongyu Zhao, Xiang Wan,
 and Can Yang. Mendelian randomization for causal inference accounting for pleiotropy
 and sample structure using genome-wide summary statistics. *Proceedings of the National Academy of Sciences*, 119(28):e2106858119, 2022.
- ⁶⁹⁶ [20] Guanghao Qi and Nilanjan Chatterjee. Mendelian randomization analysis using mixture
 ⁶⁹⁷ models for robust and efficient estimation of causal effects. *Nature Communications*,
 ⁶⁹⁸ 10(1):1941, 2019.
- [21] Stephen Burgess, Christopher N Foley, Elias Allara, James R Staley, and Joanna MM
 Howson. A robust and efficient method for mendelian randomization with hundreds of
 genetic variants. *Nature communications*, 11(1):376, 2020.

[22] Qing Cheng, Xiao Zhang, Lin S Chen, and Jin Liu. Mendelian randomization accounting
 for complex correlated horizontal pleiotropy while elucidating shared genetic etiology.
 Nature Communications, 13(1):6400, 2022

- Nature Communications, 13(1):6490, 2022.
- [23] Ben Brumpton, Eleanor Sanderson, Karl Heilbron, Fernando Pires Hartwig, Sean Harrison,
 Gunnhild Åberge Vie, Yoonsu Cho, Laura D Howe, Amanda Hughes, Dorret I Boomsma,
 et al. Avoiding dynastic, assortative mating, and population stratification biases
 in mendelian randomization through within-family analyses. *Nature communications*,
 11(1):3519, 2020.
- [24] Eleanor Sanderson, Tom G Richardson, Gibran Hemani, and George Davey Smith. The use
 of negative control outcomes in Mendelian Randomisation to detect potential population
 stratification or selection bias. *International Journal of Epidemiology*, 50(4):1350–1361,
 2021.
- ⁷¹⁴ [25] Fernando Pires Hartwig, Neil Martin Davies, and George Davey Smith. Bias in mendelian ⁷¹⁵ randomization due to assortative mating. *Genetic epidemiology*, 42(7):608–620, 2018.
- [26] Nadia Solovieff, Chris Cotsapas, Phil H Lee, Shaun M Purcell, and Jordan W Smoller.
 Pleiotropy in complex traits: challenges and strategies. *Nature Reviews Genetics*, 2013.
- [27] Stephen Burgess, Adam Butterworth, and Simon G Thompson. Mendelian randomization
 analysis with multiple genetic variants using summarized data. *Genetic epidemiology*,
 37(7):658–665, 2013.
- [28] Jack Bowden, Fabiola Del Greco M, Cosetta Minelli, George Davey Smith, Nuala Sheehan,
 and John Thompson. A framework for the investigation of pleiotropy in two-sample
 summary data mendelian randomization. *Statistics in medicine*, 36(11):1783–1802, 2017.
- [29] Alexander I Young, Stefania Benonisdottir, Molly Przeworski, and Augustine Kong.
 Deconstructing the sources of genotype-phenotype associations in humans. *Science*, 365(6460):1396–1400, 2019.
- [30] Laurence J Howe, Michel G Nivard, Tim T Morris, Ailin F Hansen, Humaira Rasheed,
 Yoonsu Cho, Geetha Chittoor, Rafael Ahlskog, Penelope A Lind, Teemu Palviainen, et al.
 Within-sibship genome-wide association analyses decrease bias in estimates of direct genetic
 effects. *Nature genetics*, 54(5):581–592, 2022.
- [31] Zhongshang Yuan, Lu Liu, Ping Guo, Ran Yan, Fuzhong Xue, and Xiang Zhou.
 Likelihood-based mendelian randomization analysis with automated instrument selection
 and horizontal pleiotropic modeling. *Science Advances*, 8(9):eabl5744, 2022.
- [32] Po-Ru Loh, Gleb Kichaev, Steven Gazal, Armin P Schoech, and Alkes L Price. Mixed-model
 association for biobank-scale datasets. *Nature genetics*, 50(7):906–908, 2018.
- [33] Eric Tchetgen Tchetgen, BaoLuo Sun, and Stefan Walter. The GENIUS approach to
 robust Mendelian randomization inference. *Statistical Science*, 36(3):443–464, 2021.

- ⁷³⁸ [34] Ting Ye, Zhonghua Liu, Baoluo Sun, and Eric Tchetgen Tchetgen. GENIUS-MAWII: For
- Robust Mendelian Randomization with Many Weak Invalid Instruments. arXiv preprint
 arXiv:2107.06238, 2021.
- [35] Zhonghua Liu, Ting Ye, Baoluo Sun, Mary Schooling, and Eric Tchetgen Tchetgen. On
 mendelian randomization mixed-scale treatment effect robust identification (mr misteri)
 and estimation for causal inference. arXiv preprint arXiv:2009.14484, 2020.
- [36] Nicola Pirastu, Ciara McDonnell, Eryk J Grzeszkowiak, Ninon Mounier, Fumiaki Imamura,
 Jordi Merino, Felix R Day, Jie Zheng, Nele Taba, Maria Pina Concas, et al. Using genetic
 variation to disentangle the complex relationship between food intake and health outcomes.
 PLoS Genetics, 18(6):e1010162, 2022.
- [37] Richard Karlsson Linnér, Pietro Biroli, Edward Kong, S Fleur W Meddens, Robbee
 Wedow, Mark Alan Fontana, Maël Lebreton, Stephen P Tino, Abdel Abdellaoui, Anke R
 Hammerschlag, et al. Genome-wide association analyses of risk tolerance and risky
 behaviors in over 1 million individuals identify hundreds of loci and shared genetic
 influences. *Nature genetics*, 51(2):245–257, 2019.
- [38] Joris Deelen, Daniel S Evans, Dan E Arking, Niccolò Tesi, Marianne Nygaard, Xiaomin
 Liu, Mary K Wojczynski, Mary L Biggs, Ashley van Der Spek, Gil Atzmon, et al. A
 meta-analysis of genome-wide association studies identifies multiple longevity genes. Nature
 communications, 10(1):3669, 2019.
- [39] Paul RHJ Timmers, Ninon Mounier, Kristi Lall, Krista Fischer, Zheng Ning, Xiao Feng,
 Andrew D Bretherick, David W Clark, Xia Shen, et al. Genomics of 1 million parent
 lifespans implicates novel pathways and common diseases and distinguishes survival chances.
 elife, 8:e39856, 2019.
- [40] Aleksandr Zenin, Yakov Tsepilov, Sodbo Sharapov, Evgeny Getmantsev, LI Menshikov,
 Peter O Fedichev, and Yurii Aulchenko. Identification of 12 genetic loci associated with
 human healthspan. *Communications biology*, 2(1):41, 2019.
- [41] Victoria Roberts, Barry Main, Nicholas J Timpson, and Simon Haworth. Genome-wide
 association study identifies genetic associations with perceived age. *Journal of Investigative Dermatology*, 140(12):2380–2385, 2020.
- [42] Janice L Atkins, Juulia Jylhävä, Nancy L Pedersen, Patrik K Magnusson, Yi Lu, Yunzhang
 Wang, Sara Hägg, David Melzer, Dylan M Williams, and Luke C Pilling. A genome-wide
 association study of the frailty index highlights brain pathways in ageing. Aging Cell,
 20(9):e13459, 2021.
- [43] Irene Pappa, Beate St Pourcain, Kelly Benke, Alana Cavadino, Christian Hakulinen,
 Michel G Nivard, Ilja M Nolte, Carla MT Tiesler, Marian J Bakermans-Kranenburg,
 Gareth E Davies, et al. A genome-wide approach to children's aggressive behavior:
 The eagle consortium. American Journal of Medical Genetics Part B: Neuropsychiatric
 Genetics, 171(5):562–572, 2016.

776 [44] Suzanne Vogelezang, Jonathan P Bradfield, Tarunveer S Ahluwalia, John A Curtin,

Timo A Lakka, Niels Grarup, Markus Scholz, Peter J Van der Most, Claire Monnereau,

- Evie Stergiakouli, et al. Novel loci for childhood body mass index and shared heritability
- with adult cardiometabolic traits. $PLoS \ genetics, 16(10):e1008718, 2020.$
- [45] Beben Benyamin, BSt Pourcain, Oliver S Davis, Gail Davies, Narelle K Hansell, M-JA
 Brion, RM Kirkpatrick, Rolieke AM Cents, Sanja Franić, MB Miller, et al. Childhood
 intelligence is heritable, highly polygenic and associated with fnbp1l. *Molecular psychiatry*, 19(2):253–258, 2014.
- [46] Nicole M Warrington, Robin N Beaumont, Momoko Horikoshi, Felix R Day, Øyvind
 Helgeland, Charles Laurin, Jonas Bacelis, Shouneng Peng, Ke Hao, Bjarke Feenstra, et al.
 Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic
 risk factors. *Nature genetics*, 51(5):804–814, 2019.
- [47] Diana L Cousminer, Diane J Berry, Nicholas J Timpson, Wei Ang, Elisabeth Thiering,
 Enda M Byrne, H Rob Taal, Ville Huikari, Jonathan P Bradfield, Marjan Kerkhof, et al.
 Genome-wide association and longitudinal analyses reveal genetic loci linking pubertal
 height growth, pubertal timing and childhood adiposity. *Human molecular genetics*,
 22(13):2735–2747, 2013.
- [48] Brendan K Bulik-Sullivan, Po-Ru Loh, Hilary K Finucane, Stephan Ripke, Jian Yang,
 Schizophrenia Working Group of the Psychiatric Genomics Consortium, Nick Patterson,
 Mark J Daly, Alkes L Price, and Benjamin M Neale. Ld score regression distinguishes
 confounding from polygenicity in genome-wide association studies. *Nature genetics*,
 47(3):291–295, 2015.
- [49] Jingshu Wang, Qingyuan Zhao, Jack Bowden, Gibran Hemani, George Davey Smith,
 Dylan S Small, and Nancy R Zhang. Causal inference for heritable phenotypic risk factors
 using heterogeneous genetic instruments. *PLoS genetics*, 17(6):e1009575, 2021.
- [50] Po-Ru Loh, George Tucker, Brendan K Bulik-Sullivan, Bjarni J Vilhjalmsson, Hilary K
 Finucane, Rany M Salem, Daniel I Chasman, Paul M Ridker, Benjamin M Neale, Bonnie
 Berger, et al. Efficient bayesian mixed-model analysis increases association power in large
 cohorts. *Nature genetics*, 47(3):284–290, 2015.
- [51] Scandinavian Simvastatin Survival Study Group et al. Randomised trial of cholesterol
 lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival
 study (4s). *The Lancet*, 344(8934):1383–1389, 1994.
- [52] C Packard, J Shepherd, S Cobbe, I Ford, CG Isles, JH McKillop, PW Macfarlane,
 AR Lorimer, and J Norrie. Influence of pravastatin and plasma lipids on clinical events in
 the west of scotland coronary prevention study (woscops). *Circulation*, 97(15):1440–1445,
 1998.
- [53] Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
 Prevention of cardiovascular events and death with pravastatin in patients with coronary

heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339(19):1349–1357, 1998.

- ⁸¹⁶ [54] National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
 ⁸¹⁷ and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third
 ⁸¹⁸ report of the national cholesterol education program (ncep) expert panel on detection,
 ⁸¹⁹ evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii)
 ⁸²⁰ final report. *Circulation*, 106(25):3143—3421, December 2002.
- ⁸²¹ [55] Heart Protection Study Collaborative Group et al. Mrc/bhf heart protection study
 of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised
 placebocontrolled trial. *The Lancet*, 360(9326):7–22, 2002.
- Epidemiological Studies Unit. Efficacy and safety of cholesterol-lowering treatment:
 prospective meta-analysis of data from 90 056 participants in 14 randomised trials of
 statins. Lancet, 366(9493):1267-1278, 2005.

[57] Haruo Nakamura, Kikuo Arakawa, Hiroshige Itakura, Akira Kitabatake, Yoshio Goto,
Takayoshi Toyota, Noriaki Nakaya, Shoji Nishimoto, Masaharu Muranaka, Akira
Yamamoto, et al. Primary prevention of cardiovascular disease with pravastatin in japan
(mega study): a prospective randomised controlled trial. *The Lancet*, 368(9542):1155–1163,
2006.

- [58] Sekar Kathiresan, Cristen J Willer, Gina M Peloso, Serkalem Demissie, Kiran Musunuru,
 Eric E Schadt, Lee Kaplan, Derrick Bennett, Yun Li, Toshiko Tanaka, et al. Common
 variants at 30 loci contribute to polygenic dyslipidemia. *Nature genetics*, 41(1):56–65,
 2009.
- ⁸³⁶ [59] Tanya M Teslovich, Kiran Musunuru, Albert V Smith, Andrew C Edmondson, Ioannis M
 ⁸³⁷ Stylianou, Masahiro Koseki, James P Pirruccello, Samuli Ripatti, Daniel I Chasman,
 ⁸³⁸ Cristen J Willer, et al. Biological, clinical and population relevance of 95 loci for blood
 ⁸³⁹ lipids. Nature, 466(7307):707-713, 2010.
- [60] Cristen J Willer, Ellen M Schmidt, Sebanti Sengupta, Gina M Peloso, Stefan Gustafsson,
 Stavroula Kanoni, Andrea Ganna, Jin Chen, Martin L Buchkovich, Samia Mora, et al.
 Discovery and refinement of loci associated with lipid levels. *Nature genetics*, 45(11):1274,
 2013.
- [61] Sarah E Graham, Shoa L Clarke, Kuan-Han H Wu, Stavroula Kanoni, Greg JM Zajac,
 Shweta Ramdas, Ida Surakka, Ioanna Ntalla, Sailaja Vedantam, Thomas W Winkler,
 et al. The power of genetic diversity in genome-wide association studies of lipids. *Nature*,
 600(7890):675-679, 2021.
- ⁸⁴⁸ [62] the CARDIoGRAMplusC4D Consortium. A comprehensive 1000 genomes-based genome⁸⁴⁹ wide association meta-analysis of coronary artery disease. *Nature genetics*, 47(10):1121⁸⁵⁰ 1130, 2015.